Breaking News Instant updates and real-time market news.

BIIB

Biogen

$311.59

-1.44 (-0.46%)

, IONS

Ionis Pharmaceuticals

$36.03

-0.61 (-1.66%)

09:08
10/04/16
10/04
09:08
10/04/16
09:08

Biogen could rise $20 or more per share on SMA success, says RBC Capital

RBC Capital analyst Michael Yee expects the first presentation of data from Biogen's (BIIB) Phase III ENDEAR trial studying nusinersen, an investigational treatment for spinal muscular atrophy, or SMA, this week, potentially during the late breaker session at the WMS Congress on October 8. Biogen and partner Ionis Pharmaceuticals (IONS) already announced in August that the study in Type I infants hit the interim analysis and stopped early for positive data. The much larger opportunity in older children has data expected to read out in Spring 2017, noted Yee, who thinks Biogen can have upside from $10 to over $20 per share based on its SMA opportunity. Yee keeps an Outperform rating and $375 price target on Biogen shares.

BIIB

Biogen

$311.59

-1.44 (-0.46%)

IONS

Ionis Pharmaceuticals

$36.03

-0.61 (-1.66%)

  • 26

    Oct

  • 06

    Nov

BIIB Biogen
$311.59

-1.44 (-0.46%)

09/26/16
PIPR
09/26/16
NO CHANGE
Target $46
PIPR
Overweight
Ionis nusinersen program advancing faster than expected, says Piper Jaffray
After Biogen (BIIB) and Ionis (IONS) announced that Biogen has completed the rolling submission of a New Drug Application to the U.S. FDA for the approval of nusinersen, an investigational treatment for spinal muscular atrophy, Piper Jaffray analyst Joshua Schimmer said that the nusinersen program is advancing faster than many have expected. Nusinersen may launch before AveXis (AVXS) starts its next Phase 3 trial, added Schimmer, who believes nusinersen will emerge as a multi-billion dollar product. The analyst keeps an Overweight rating and $46 price target on Ionis shares.
09/28/16
JEFF
09/28/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies parent survey shows interest in AveXis pivotal trial
Jefferies analyst Biren Amin conducted a survey of parents of spinal muscular atrophy patients amid investor questions surrounding AveXis' (AVXS) ability to enroll a pivotal trial with AVXS-101 given the open access program with nusinersen, the investigational drug being developed by Ionis Pharmaceuticals (IONS) and Biogen (BIIB). Parents value the option of nusinersen treatment but are also willing to enroll in clinical trials of AVXS-101, Amin tells investors in a research note, citing his survey of seven parents. A single arm trial of AVXS-101 was the most preferred clinical trial design for the upcoming Phase 3 of AVXS-101, he added. The analyst believes his parent responses suggest excitement over nusinersen but also a willingness to enroll into the AVXS-101 trials, especially if it is a single-arm trial. Parents were also attracted to AVXS-101 intravenous delivery, which could be a "meaningful advantage," Amin contends. The analyst keeps a Buy rating on AveXis with a $50 price target. The stock closed yesterday up 88c to $41.00. Amin caused a rally in AveXis shares on September 19 when writing about finding a video online of a spinal muscular atrophy baby walking that he believed to be a patient in the company's trial of AVXS-101.
09/28/16
BERN
09/28/16
NO CHANGE
BERN
Biogen likely to benefit from Lilly Alzheimer's drug results, says Bernstein
Bernstein analyst Aaron Gal says that the results of a trial of Eli Lilly's (LLY) Alzheimer's drug, solanezumab, due out in late 2016 or early 2017, are likely to impact perceptions of Biogen's (BIIB) Alzheimer's drug, aducanumab. The analyst expects Lilly's solanezumab "to show at least directional evidence" of cognitive improvement, although he is "less convinced" that the impact will be clearly statistically significant. The best results from Biogen's perspective will be if Lilly's drug shows "marginal success," according to Gal. However, statistically significant results are also good for Biogen, as they will show that reducing amyloid beta does mitigate Alzheimer's symptoms, the analyst stated. And if Lilly's drug completely fails, Biogen's drug "could well succeed," given the significant differences between them, wrote Gal,who gives Biogen's aducanumab a 65% chance of success. He keeps a $345 price target and Outperform rating on Biogen.
10/03/16
BMOC
10/03/16
NO CHANGE
Target $304
BMOC
Biogen potential trading opportunity into year-end, says BMO Capital
BMO Capital hosted a call with an expert on Alzheimers that may present a trading opportunity in Biogen (BIIB) shares as we approach sola Phase 3 and aducanumab titration data expected at year end. The expert said evidence supports the amyloid hypothesis of AD outweighs the evidence that undercuts it, but suggested that patient selection and trial design/execution key to demonstrating benefit to support regulatory approval. He estimated that Lilly's (LLY) EXPEDITION-3 trial has a ~60% probability of success, with Biogen's aducanumab greater than70% as long as rates of ARIA-E can be reduced with titration. Analyst Ian Somaiya believes positive Phase III Sola data could provide a positive read through to aducanumab and results in Biogen shares trading up 20-25%. If Sola misses, aducanumab's ability to clear beta amyloid oligomers & plaques and in our opinion a better trial design could limit downside in shares to approximately 10%. Somaiya rates Biogen a Market Perform with a $304 price target.
IONS Ionis Pharmaceuticals
$36.03

-0.61 (-1.66%)

08/22/16
WEDB
08/22/16
NO CHANGE
WEDB
Intellia Therapeutics data positive, says Wedbush
Wedbush analyst David Nierengarten says that additional data on Intella's (NTLA) TTR program in mice was "meaningful" and indicates that the program compares favorably with competing products. The analyst says that competing programs, including those of Alnylam (ALNY) and Ionis (IONS) have shown "only a transient benefit." He reiterates a $38 price target and Outperform rating on Intella.
09/28/16
JANY
09/28/16
INITIATION
Target $47
JANY
Buy
Ionis Pharmaceuticals initiated with a Buy at Janney Capital
Janney Capital analyst Roy Buchanan initiated Ionis Pharmaceuticals with a Buy and a $47 fair value estimate. Buchanan believes the late stage pipeline, including wholly-owned volanesorsen, and the base technology can add meaningful value to Ionis. 1H 2017 is particularly rich with 3 phase 3 readouts, with potential for another early, interim look at SMA.

TODAY'S FREE FLY STORIES

MTN

Vail Resorts

$160.92

-1.81 (-1.11%)

20:25
12/08/16
12/08
20:25
12/08/16
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

MON

Monsanto

$104.70

-0.71 (-0.67%)

20:17
12/08/16
12/08
20:17
12/08/16
20:17
Hot Stocks
Washington sues Monsanto over PCB contamination »

Washington Attorney…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 27

    Jan

USAC

USA Compression

$18.01

-0.14 (-0.77%)

20:15
12/08/16
12/08
20:15
12/08/16
20:15
Syndicate
USA Compression 4.5M share Spot Secondary priced at $16.25 »

The deal range was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

ICHR

Ichor Holdings

20:11
12/08/16
12/08
20:11
12/08/16
20:11
Syndicate
Ichor Holdings 5.9M share IPO priced at $9.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

GOOG

Alphabet

$776.42

5.23 (0.68%)

, GOOGL

Alphabet Class A

$795.17

3.7 (0.47%)

19:53
12/08/16
12/08
19:53
12/08/16
19:53
Periodicals
YouTube-NMPA settlement estimated at over $40M, NY Times says »

The agreement between…

GOOG

Alphabet

$776.42

5.23 (0.68%)

GOOGL

Alphabet Class A

$795.17

3.7 (0.47%)

SNE

Sony

$29.16

0.55 (1.92%)

VIVHY

Vivendi

$18.83

-0.455 (-2.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

GOOG

Alphabet

$776.42

5.23 (0.68%)

, GOOGL

Alphabet Class A

$795.17

3.7 (0.47%)

19:46
12/08/16
12/08
19:46
12/08/16
19:46
Hot Stocks
YouTube reaches agreement to pay out unclaimed song royalties »

The National Music…

GOOG

Alphabet

$776.42

5.23 (0.68%)

GOOGL

Alphabet Class A

$795.17

3.7 (0.47%)

SNE

Sony

$29.16

0.55 (1.92%)

VIVHY

Vivendi

$18.83

-0.455 (-2.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

ATH

Athene Holding

19:33
12/08/16
12/08
19:33
12/08/16
19:33
Syndicate
Athene Holding 27M share IPO priced at $40.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

MMM

3M

$175.88

-0.17 (-0.10%)

19:29
12/08/16
12/08
19:29
12/08/16
19:29
Hot Stocks
3M to sell identity management business to Gemalto for $850M »

3M announced that it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

SMI

SMIC

$5.99

-0.54 (-8.27%)

19:24
12/08/16
12/08
19:24
12/08/16
19:24
Hot Stocks
SMIC announces 10-for-1 reverse stock split »

Semiconductor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VTR

Ventas

$62.61

0.41 (0.66%)

19:10
12/08/16
12/08
19:10
12/08/16
19:10
Hot Stocks
Ventas raises quarterly dividend 6% to 77.5c per share »

Ventas said that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$57.29

0.01 (0.02%)

19:08
12/08/16
12/08
19:08
12/08/16
19:08
Periodicals
Wells Fargo chairman appointed to sales investigation committee, Reuters says »

Wells Fargo chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

WFC

Wells Fargo

$57.29

0.01 (0.02%)

19:03
12/08/16
12/08
19:03
12/08/16
19:03
Periodicals
Former Wells Fargo managers file suit over fake accounts, Bloomberg reports »

Three former Wells Fargo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

EIX

Edison International

$69.44

-0.17 (-0.24%)

18:42
12/08/16
12/08
18:42
12/08/16
18:42
Hot Stocks
Edison International raises annual dividend 13% to $2.17 per share »

Edison International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLM

PolyMet Mining

$0.87

0.0001 (0.01%)

18:24
12/08/16
12/08
18:24
12/08/16
18:24
Earnings
Breaking Earnings news story on PolyMet Mining »

PolyMet Mining reports Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTCH

Match Group

$18.38

0.18 (0.99%)

18:24
12/08/16
12/08
18:24
12/08/16
18:24
Hot Stocks
Match Group launches 'Swipe Ventures,' says Tinder CEO to step down »

Match Group's Tinder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$289.54

4.24 (1.49%)

18:18
12/08/16
12/08
18:18
12/08/16
18:18
Hot Stocks
Biogen to present aducanumab Phase 1b data at CTAD meeting »

Biogen announced it will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

HIVE

Aerohive

$5.41

0.18 (3.44%)

18:17
12/08/16
12/08
18:17
12/08/16
18:17
Hot Stocks
Discovery Group reports 9.1% stake in Aerohive Networks, sends letter to board »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENLK

EnLink Midstream Partners

$17.45

0.2 (1.16%)

, ENLC

EnLink Midstream

$18.20

0.1 (0.55%)

18:05
12/08/16
12/08
18:05
12/08/16
18:05
Periodicals
Outrigger Energy nears sale to midstream services provider, Forbes says »

Private-equity backed…

ENLK

EnLink Midstream Partners

$17.45

0.2 (1.16%)

ENLC

EnLink Midstream

$18.20

0.1 (0.55%)

TRGP

Targa Resources

$54.20

0.38 (0.71%)

ETP

Energy Transfer Partners

$35.13

0.55 (1.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POST

Post Holdings

$78.65

0.96 (1.24%)

18:02
12/08/16
12/08
18:02
12/08/16
18:02
Hot Stocks
Post Holdings settles egg antitrust class action claims »

Post Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENZN

Enzon

$0.44

-0.0027 (-0.62%)

17:54
12/08/16
12/08
17:54
12/08/16
17:54
Hot Stocks
Icahn says enters standstill pact with Enzon »

In an amended filing on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LDOS

Leidos

$52.27

0.15 (0.29%)

17:53
12/08/16
12/08
17:53
12/08/16
17:53
Hot Stocks
Leidos awarded $350M government contract »

Leidos, Reston, Virginia,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDC

Dominion Diamond

$10.27

0.21 (2.09%)

17:50
12/08/16
12/08
17:50
12/08/16
17:50
Hot Stocks
Dominion Diamond sees FY17 production at Ekati diamond mine 4.5M carats »

Sees FY17 Ekati diamond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

FNSR

Finisar

$34.13

1.89 (5.86%)

, AVGO

Broadcom

$170.71

2.16 (1.28%)

17:49
12/08/16
12/08
17:49
12/08/16
17:49
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

FNSR

Finisar

$34.13

1.89 (5.86%)

AVGO

Broadcom

$170.71

2.16 (1.28%)

GLPG

Galapagos NV

$58.95

0.71 (1.22%)

XTLY

Xactly

$14.35

0.35 (2.50%)

RH

Restoration Hardware

$38.99

1.05 (2.77%)

DLTH

Duluth Holdings

$37.04

3.09 (9.10%)

NCS

NCI Building

$17.85

0.6 (3.48%)

FRED

Fred's

$10.84

0.15 (1.40%)

USAC

USA Compression

$18.01

-0.14 (-0.77%)

FRO

Frontline

$7.71

0.37 (5.04%)

WSM

Williams-Sonoma

$56.90

0.61 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

  • 08

    Dec

  • 08

    Dec

  • 08

    Dec

  • 08

    Dec

  • 09

    Dec

  • 13

    Dec

  • 14

    Dec

  • 09

    Dec

ESRX

Express Scripts

$70.75

-5.1 (-6.72%)

, ANTM

Anthem

$146.61

1.41 (0.97%)

17:48
12/08/16
12/08
17:48
12/08/16
17:48
Hot Stocks
Citron's Andrew Left: 'By no means' calling Express Scripts a fraud or zero »

Speaking in a CNBC…

ESRX

Express Scripts

$70.75

-5.1 (-6.72%)

ANTM

Anthem

$146.61

1.41 (0.97%)

CVS

CVS Health

$78.11

-2.42 (-3.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

DDC

Dominion Diamond

$10.27

0.21 (2.09%)

17:45
12/08/16
12/08
17:45
12/08/16
17:45
Earnings
Dominion Diamond reports Q3 EPS 34c with items, consensus (32c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.